Show simple item record

dc.contributor.authorGraner, Sophieen_US
dc.contributor.authorSvensson, Tobiasen_US
dc.contributor.authorBeau, Anna-Belleen_US
dc.contributor.authorDamase-Michel, Christineen_US
dc.contributor.authorEngeland, Andersen_US
dc.contributor.authorFuru, Karien_US
dc.contributor.authorHviid, Andersen_US
dc.contributor.authorHåberg, Siri Eldeviken_US
dc.contributor.authorMølgaard-Nielsen, Ditteen_US
dc.contributor.authorPasternak, Björnen_US
dc.contributor.authorKieler, Helleen_US
dc.PublishedGraner, Svensson, Beau, Damase-Michel C, Engeland A, Furu K, Hviid A, Håberg SE, Mølgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ-British Medical Journal. 2017;356:j629eng
dc.description.abstractObjective: To evaluate the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life with respect to adverse neonatal outcomes and congenital malformations. Design: Population based multinational observational cohort study and meta-analysis. Setting: National registers covering information on maternal healthcare, births, and prescriptions in Denmark, Norway, and Sweden and the EFEMERIS database from the Haute-Garonne district in France. Participants: All women together with their singleton infants born between 1 January 2008 and 31 December 2010. Only infants born at 154 days of gestation or later were included. Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors oseltamivir or zanamivir. Main outcomes: Low birth weight, low Apgar score, preterm birth, small for gestational age birth, stillbirth, neonatal mortality, neonatal morbidity, and congenital malformations. Crude and adjusted hazard ratios of preterm birth were estimated using Cox regression models. Crude and adjusted odds ratios for other outcomes were estimated by logistic regression models. Results: The study included 5824 (0.8%) exposed women and their infants and 692 232 who were not exposed. Exposure to neuraminidase inhibitors in utero was not associated with increased risks of any of the investigated neonatal outcomes, including low birth weight (adjusted odds ratio 0.77, 95% confidence interval 0.65 to 0.91), low Apgar score (adjusted odds ratio 0.87, 0.67 to 1.14), preterm birth (adjusted hazard ratio 0.97, 0.86 to 1.10), small for gestational age birth (adjusted odds ratio 0.72, 0.59 to 0.87), stillbirth (adjusted odds ratio 0.81, 0.51 to 1.30), neonatal mortality (adjusted odds ratio 1.13, 0.56 to 2.28), and neonatal morbidity (adjusted odds ratio 0.92, 0.86 to 1.00). No increased risk of congenital malformations overall associated with maternal exposure was observed during the first trimester (adjusted odds ratio 1.06, 0.77 to 1.48). Similarly, no significantly increased risks of any of the outcomes were observed in an analysis restricted to oseltamivir alone. Conclusions: This large multinational register study found no increased risks of adverse neonatal outcomes or congenital malformations associated with exposure to neuraminidase inhibitors during embryo-fetal life. The results support previously reported findings that the use of neuraminidase inhibitors is not associated with increased risks of adverse fetal or neonatal outcomes.en_US
dc.rightsAttribution CC BY-NCeng
dc.titleNeuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)
dc.source.journalBMJ (British Medical Journal)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY-NC
Except where otherwise noted, this item's license is described as Attribution CC BY-NC